RIFT VALLEY FEVER VIRUS-LIKE PARTICLES AND THEIR USE FOR IMMUNIZATION AND AS TEST SYSTEM
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 9, 2009
filing date -
Jun 10, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed is a method for producing virus-like particles (VLP) that comprises the steps of (a) transfecting a mammalian cell line with several independent vectors, including (1) a vector containing at least a substantial part of the M gene from Rift Valley Fever Virus, (2) a vector containing at least a substantial part of the L gene from Rift Valley Fever Virus, (3) a vector containing at least a substantial part of the N gene from Rift Valley Fever Virus and (4) a vector containing a multicloning site flanked by the non-coding 5′- and 3′-ends of the L-, M- or S-segment of Rift Valley Fever Virus, and (b) culturing the transfected mammalian cell line under suitable conditions and obtaining the VLPs from the supernatant of the transfected cultured cell lines. The so-obtained VLPs can be used for vaccination and in methods for testing the antiviral activity of compounds.
First Claim
Family
International Classification(s)
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C12Q:MEASURING OR TESTING PROCESSES INVOLVING ENZYMES O....
- C12P:FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESI....
- G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....
- A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully